NCT06346392
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatmentAstraZeneca
~594 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:AZD0901Ramucirumab+ paclitaxelPaclitaxelDocetaxelIrinotecanTAS-102
At a glance
Recruiting sites
0 of 158 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression Free Survival (PFS) in all randomized participants
Measured over From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).
+1 more outcome measured
Conditions
Where it's being run
158 sites across 34 statesChina35
Germany11
Japan10
Poland8
Italy7
Spain7
Taiwan7
South Korea6
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Progression Free Survival (PFS) in all randomized participantsFrom date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).
The analysis will include all randomized participants. All events will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy.
- Overall Survival (OS) for 3L+ participantsFrom date of first dose/randomisation until the date of death due to any cause (approximately 3 years).
The analysis will include all randomized participants who had at least 2 prior lines of systemic therapy. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy.